261 related articles for article (PubMed ID: 19963097)
21. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
Miyake H; Fujisawa M
Hinyokika Kiyo; 2012 Nov; 58(11):651-4. PubMed ID: 23254795
[TBL] [Abstract][Full Text] [Related]
22. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
Boni JP; Hug B; Leister C; Sonnichsen D
Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
[TBL] [Abstract][Full Text] [Related]
23. Temsirolimus: a safety and efficacy review.
Bukowski RM
Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
[TBL] [Abstract][Full Text] [Related]
24. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
Dancey JE; Curiel R; Purvis J
Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
[TBL] [Abstract][Full Text] [Related]
25. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
26. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
27. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
Gerullis H; Bergmann L; Maute L; Eimer C; Otto T
Cancer Chemother Pharmacol; 2009 May; 63(6):1097-102. PubMed ID: 18818922
[TBL] [Abstract][Full Text] [Related]
28. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
29. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
31. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
Lamm W; Vogl UM; Bojic M; Zielinski C; Klingler C; Kramer G; Schmidinger M
Acta Oncol; 2012 Jan; 51(1):101-6. PubMed ID: 21736504
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
[TBL] [Abstract][Full Text] [Related]
35. Temsirolimus for advanced renal cell carcinoma.
Bergmann L; Maute L; Guschmann M
Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
[TBL] [Abstract][Full Text] [Related]
36. Clinical development of temsirolimus, a novel mTOR inhibitor, for treatment of advanced malignancies.
Dancey JE
Semin Oncol; 2009 Dec; 36 Suppl 3():S1-2. PubMed ID: 19963095
[No Abstract] [Full Text] [Related]
37. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
38. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
[TBL] [Abstract][Full Text] [Related]
39. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
40. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.
Lee CK; Marschner IC; Simes RJ; Voysey M; Egleston B; Hudes G; de Souza P
Clin Cancer Res; 2012 Jun; 18(11):3188-96. PubMed ID: 22472176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
